HUTCHMED (China) Limited (HKG:0013)
25.70
+0.50 (1.98%)
Aug 15, 2025, 4:08 PM HKT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,811 employees as of December 31, 2024. The number of employees decreased by 177 or -8.90% compared to the previous year.
Employees
1,811
Change (1Y)
-177
Growth (1Y)
-8.90%
Revenue / Employee
2.66M HKD
Profits / Employee
2.06M HKD
Market Cap
22.17B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,811 | -177 | -8.90% |
Dec 31, 2023 | 1,988 | -37 | -1.83% |
Dec 31, 2022 | 2,025 | 265 | 15.06% |
Dec 31, 2021 | 1,760 | 480 | 37.50% |
Dec 31, 2020 | 1,280 | 427 | 50.06% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
BeOne Medicines | 11,000 |
Hansoh Pharmaceutical Group Company | 8,989 |
JD Health International | 3,564 |
Innovent Biologics | 5,659 |
Akeso | 3,035 |
Sino Biopharmaceutical | 24,379 |
WuXi Biologics | 12,575 |
CSPC Pharmaceutical Group | 21,400 |
HUTCHMED (China) News
- 8 days ago - HUTCHMED (China) Limited (HCM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - HUTCHMED to Announce 2025 Half-Year Financial Results - GlobeNewsWire
- 6 weeks ago - HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy - GlobeNewsWire
- 2 months ago - HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - GlobeNewsWire
- 2 months ago - HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer - Benzinga
- 4 months ago - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 - GlobeNewsWire